I n this issue of The Annals, researchers from the Central Ohio Poison Control Center conducted a study to identify populations at increased risk for adverse events (AEs) secondary to ephedra weight-loss supplements. 1 The researchers used information provided by individual callers to their poison center. The data were cross-tabulated in relationship to demographics such as patient weight, age, gender, and medical history.
Results indicated that women who abused or misused ephedra were at increased risk for AEs. This finding parallels results of a survey of usage patterns of nonprescription weight-loss products in which higher prevalence of use was found in young, obese women. 2 The study also found that 81% of unintentional ingestions of ephedra occurred in boys <12 years of age. The higher risk in boys has not been previously reported in the literature. However, this finding seems logical, since studies have shown that boys <13 years old are more likely than girls to be involved in unintentional poisoning. 3 Authentication of the information in the study 1 was not always possible, since not all callers were seen in a healthcare facility. Patients who consume ephedra may be intrinsically more likely to have serious AEs compared with those who use other dietary supplements. In addition, whether the AEs caused by ephedra were reported due to public awareness of potential dangers because of recent media attention was not determined. Also, since the study did not analyze the ephedra products as to content, concentration, or presence of other stimulants, the effect of adulteration or inappropriate dosage could not be assessed. Therefore, the authors were unable to establish definitive causal evidence for risk of serious injury due to ephedra.
Additional evidence obtained from randomized, prospective controlled studies is needed to evaluate the safety of ephedra, but it is unlikely that such studies could be powered enough to detect a significant difference in serious AEs to resolve safety questions. In addition, the ethical dilemma of conducting a clinical trial evaluating the safety of ephedra is debatable.
Ephedra, also known as ma huang, has been used in Asia for thousands of years for treatment of respiratory diseases such as asthma and bronchitis. 4,5 More recently, ephedra has become a popular ingredient in dietary supplements that are promoted for weight loss, increasing energy, and enhancing athletic performance. 5 Ephedra is often part of multicomponent dietary supplements that include other herbals such as Citrus durantium and Garcinia cambogia, and caffeine, as well as caffeine-containing herbals such as kola nut and guarana. 4, 5 The herb ephedra contains several active alkaloids, including ephedrine, pseudoephedrine, norephedrine, norpseudo-ephedrine (a schedule IV controlled substance), methylephedrine, and methylpseudoephedrine. Ephedrine, the major alkaloid, has mixed sympathomimetic activity that stimulates both αand β-adrenergic receptors. It also indirectly releases norepinephrine from storage sites. 4, 5 AEs associated with ephedra and ephedrine alkaloids include headache, hypertension, insomnia, irritability, motor restlessness, tachycardia, and urinary retention. Serious AEs include cardiac arrhythmias, myocardial infarction, psychosis, seizures, stroke, and death. 4, 5 As of 1994, ephedra products were classified as dietary supplements according to the Dietary Supplement Health and Education Act (DSHEA). 6 With passage of DSHEA, dietary supplement manufacturers, unlike manufacturers of prescription and over-the-counter drugs, do not need premarket Food and Drug Administration (FDA) approval. Once a dietary supplement is marketed, the FDA must demonstrate that the supplement is unsafe before they can remove it from the marketplace. It is estimated that the FDA receives <1% of all AE reports associated with dietary supplements. 7 Ephedra-containing dietary supplements are readily available in grocery stores, health food stores, pharmacies, and on the Internet. Since 1993, thousands of AEs associated with ephedra and botanical ephedrine alkaloid dietary supplements have been reported to the FDA. As a result, there has been a mass media frenzy on the safety of ephedra. 8 The deaths of athletes such as Korey Stringer of the Minnesota Vikings, Rashidi Wheeler of Northwestern University, DeVaughn Williams of Florida State University, and the more recent death of Orioles pitcher Steve Bechler in February 2003 were partially attributed to the use of ephedra. 9 The FDA and other government agencies have taken steps to evaluate the safety and efficacy of ephedra. 10 Major events associated with the regulation of ephedra are outlined in Table 1 . In June 1997, the FDA proposed tightening the regulation of ephedra supplements and proposed a limit on the amount of ephedrine alkaloids to ≤8 mg per serving, ≤24 mg/day, and a duration limit of 7 days. However, in 1999, the US General Accounting Office concluded that there was insufficient evidence to support the FDA's proposed restrictions.
On August 15, 2002, the US Justice Department announced it was investigating whether Metabolife (one of the major manufacturers of ephedra-containing weight-loss supplements) had made false claims to the FDA about the existence of reports concerning its products. On the same day, Metabolife announced it was releasing >13 000 AE reports to the FDA. Upon analysis of the AE reports, the House Committee on Government Reform concluded that 2000 of the reports were significant for AEs; these included 3 deaths, 20 myocardial infarctions, 24 strokes, 40 seizures, 465 reports of chest pain, and 966 episodes of arrhythmias. 9 In February 2003, results of the Rand Study, which evaluated the efficacy and safety of ephedra-containing products for weight loss and athletic performance, were published. 11 Investigators evaluated 52 controlled studies and 65 case reports and included formal meta-analyses when possible. The results suggested that short-term use produced modest weight loss (~0.9 kg/mo). There was no evidence for enhancement of athletic performance. Safety data from 50 trials showed a 2.2-to 3.6-fold increase in the risk of AEs. However, the majority of the case reports were insufficiently documented, and the actual relationship between use and AEs could not be assessed.
On December 30, 2003, the FDA alerted the public that it planned to ban dietary supplements containing ephedra because they presented "unreasonable risk of illness or injury," and on February 11, 2004 The current regulatory approach to ensure the safety of dietary supplements is confusing to many consumers. A Harris Poll found that people are often unaware of the lack of FDA requirements for the marketing of dietary supplements. 12 The majority of those surveyed assumed that dietary supplements are approved by the FDA prior to marketing and that manufacturers cannot make claims about safety unless such claims are supported by scientific evidence.
The editors of the Journal of the American Medical Association have called for major changes in the regulation of dietary supplements. 13 A spokesman from the American Medical Association urges that dietary supplement manufacturers meet standards established by the United States Pharmacopoeia for identity, purity, quality, strength, packaging, and labeling of their dietary supplements. 14 Two legislative measures that should be supported and passed are aimed at increasing the FDA's authority to ensure the safety of dietary supplements. The first endeavor is Senate Bill 722. 15 The bill would enhance the FDA's authority to require dietary supplement manufacturers to submit additional safety information for dietary supplements that are thought to pose serious health hazards to consumers. The other measure is House Rule 3377. 16 It would enhance the FDA's authority to ensure that dietary supplements are safe and will require manufacturers to report AEs.
This issue of The Annals provides more evidence as to the appropriateness of the FDA ban on the sale of ephedra dietary supplements. 1 Some groups thought the FDA should have acted sooner. However, under DSHEA, the FDA must review the evidence and prove that a dietary supplement presents an unreasonable risk of illness or injury to the consumer. The ban of ephedra is the first time the FDA has gone through the difficult steps required by DSHEA to ban a dietary supplement.
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